To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer

NCT07370818 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

81

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: JPI-547
DRUG: Bevacizumab

Sponsor

Onconic Therapeutics Inc.